252 563

Cited 0 times in

소아 악성림프종 환아에서의 조혈모세포이식 결과 : 다기관 후향적 조사

Other Titles
 Hematopoietic Stem Cell Transplantation for Children with Malignant Lymphoma in Korea: Multicenter Retrospective Study 
 김보현  ;  원성철  ;  신희영  ;  안효섭  ;  황태주  ;  국훈  ;  구홍회  ;  성기웅  ;  유건희  ;  김학기  ;  조빈  ;  정낙균  ;  박준은  ;  하정옥  ;  김태형  ;  문형남  ;  서종진  ;  박재선  ;  이영호  ;  유은선  ;  유철주 
 Korean Journal of Pediatric Hematology-Oncology (대한소아혈액종양학회지), Vol.12(1) : 18-27, 2005 
Journal Title
Korean Journal of Pediatric Hematology-Oncology(대한소아혈액종양학회지)
Issue Date
non hodgkin's lymphoma ; hodgkin's disease ; stem cell transplantation
non hodgkin's lymphoma ; hodgkin's disease ; stem cell transplantation
Purpose: Children with Malignant lymphoma who is in the advanced stage at diagnosis or relapses during treatment have a poor prognosis. Recently, hematopoietic stem cell transplantation (HSCT) for advanced stage or refractory/relapsed lymphoma performed frequently. However, the role for HSCT for children with malignant lymphoma is still controversial. In this study, we reviewed children with malignant lymphoma who received HSCT and analyzed the results.

Methods: Questionnaires were made and sent to a group of teaching hospitals, with a return of 37 questionnaires from 11 hospitals. 33 patients with Non-Hodgkin lymphoma (NHL) and 4 patients with Hodgkin disease (HD) who received HSCT from 1997 to 2004 in Korea were enrolled in this study. Disease state at diagnosis, relapses during treatment, disease state at HSCT, and survival record were analyzed. All Data were reviewed with the questionnaires from the 11 teaching hospitals.

Results: Four patients with HD received HSCT at the 2nd complete remission after relapse. Survival rate for HD was 100% and their follow up duration ranged from 0.2 to 6.2 years (median 2.4 years). The 2-year survival rate for NHL was 68.1±9.0% and their follow up duration ranged from 0.1 to 7.6 years (median 1.5 years). The 2-year survival rate in patients with advanced stage at diagnosis and in relapsed/refractory patients were 83.6±1.1% and 55.9±12.9%, respectively (P=0.12). The mortality asssociated with HSCT was only 1 case, and most of the transplantation related complications did not resulted in death.

Conclusion: Our results suggest that high dose chemotherapy followed by HSCT in children with malignant lymphoma is a safe procedure, which at the same time improves the results of standard treatment.
Files in This Item:
T200500500.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Won, Sung Chul(원성철)
Lyu, Chuhl Joo(유철주) ORCID logo https://orcid.org/0000-0001-7124-7818
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.